Commercial Progress: As of February 17, 2025, 1,028 unique patient prescriptions for Attruby have been written by 516 unique healthcare providers since FDA approval. "I am very encouraged by the strength of the Attruby launch, with prescriptions being successfully filled across all patient types," said Matt Outten, Chief Commercial Officer of BridgeBio. "In conversations with healthcare providers and patients, we have repeatedly heard that Attruby's category-leading results - time to separation of just three months, along with a 42% reduction in all-cause mortality and recurrent hospitalizations and a 50% reduction in cardiovascular hospitalizations at 30 months - set it apart as a clinically meaningful advancement for ATTR-CM. Combined with our industry-leading patient support programs, we believe Attruby is delivering a much-needed change in the treatment landscape."